PADI4 and colitis: Preclinical studies in colitis-associated cancer models show that PAD4 inhibition (e.g., Cl-amidine) (Wang et al., 2023b) and DNase I-mediated NET degradation (Zhang et al., 2023b) not only alleviate UC pathology but also suppress tumorigenesis.